Cytokinetics CEO sells shares for tax withholding

Cytokinetics Inc. President & CEO Robert I. Blum reported an open-market sale of 36,601 shares of common stock at $62.15 per share.

Accepted by SEC EDGAR 03/18/2026 - 05:37 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Cytokinetics Inc. President & CEO Robert I. Blum reported an open-market sale of 36,601 shares of common stock at $62.15 per share. According to the footnotes, these were company-compelled sell-to-cover transactions to satisfy tax withholding obligations from RSU vesting, rather than discretionary sales.

After these transactions, Blum holds 430,330 shares of common stock directly. In addition, 2,083 shares are held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares are held by The Brittany Blum 2003 Irrevocable Trust as indirect holdings.

Insider Trade Summary

Net Seller: 36,601 shares

Net Sell 2 txns

Insider Blum Robert I

Role President & CEO

Sold 36,601 shs ($2.27M)

Type	Security	Shares	Price	Value
Sale	Common Stock	12,673	$62.15	$788K
Sale	Common Stock	23,928	$62.15	$1.49M
Holding	Common Stock	--	--	--
Holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 430,330 shares (Direct); Common Stock — 2,083 shares (Indirect, by Trust 1); Common Stock — 2,083 shares (Indirect, by Trust 2)

Footnotes (4)

1. F1. Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting.
2. F2. Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting.
3. F3. Shares held by The Bridget Blum 2003 Irrevocable Trust.
4. F4. Shares held by The Brittany Blum 2003 Irrevocable Trust.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cytokinetics (CYTK) report for Robert Blum?

Cytokinetics reported that President & CEO Robert I. Blum sold 36,601 shares of common stock at $62.15 per share. Footnotes state the company compelled these sales to cover tax withholding from restricted stock unit vesting.

Were Robert Blum’s CYTK share sales discretionary open-market sales?

The filing describes the sales as open-market transactions but footnotes clarify they were company-compelled sell-to-cover trades. The purpose was to satisfy tax withholding obligations tied to vesting restricted stock units, not discretionary portfolio selling.

How many CYTK shares does Robert Blum hold after this Form 4?

After the reported transactions, Robert Blum holds 430,330 shares of Cytokinetics common stock directly. The filing also shows 2,083 shares in each of two irrevocable trusts, The Bridget Blum 2003 and The Brittany Blum 2003, as indirect holdings.

What price was received in Robert Blum’s CYTK share sales?

The reported sell-to-cover transactions were executed at $62.15 per share. These sales were undertaken to cover tax withholding obligations related to restricted stock unit vesting, as disclosed in the accompanying footnotes to the Form 4.

Do the CYTK trust holdings belong directly to Robert Blum?

The Form 4 states that 2,083 shares are held by The Bridget Blum 2003 Irrevocable Trust and 2,083 by The Brittany Blum 2003 Irrevocable Trust. These are reported as indirect holdings, reflecting shares held by the trusts rather than as direct personal holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blum Robert I

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		12,673	D	$62.15	454,258	D
Common Stock	03/17/2026		S(2)		23,928	D	$62.15	430,330	D
Common Stock								2,083	I	by Trust 1(3)
Common Stock								2,083	I	by Trust 2(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting.

2. Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting.

3. Shares held by The Bridget Blum 2003 Irrevocable Trust.

4. Shares held by The Brittany Blum 2003 Irrevocable Trust.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Blum	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)